Literature DB >> 23974107

Cell context in the control of self-renewal and proliferation regulated by MLL1.

Erika L Artinger1, Patricia Ernst.   

Abstract

Mixed lineage leukemia 1 (MLL1) is a gene that is disrupted by chromosomal translocation characteristically in a large proportion of infant leukemia and also in a fraction of childhood and adult leukemia. MLL1 encodes a chromatin regulatory protein related to the Drosophila Trithorax protein, a well-studied epigenetic factor that functions during development to maintain expression of its target genes. Although tremendous progress has been made understanding the downstream targets of MLL1 fusion oncoproteins and how manipulation of those targets impacts leukemogenesis, very little is known regarding how the initial expression of an MLL1 fusion protein impacts on that cell's behavior, particularly how the cell cycle is affected. Here, we focused on the function of endogenous MLL1 in the stem and progenitor cell types that are likely to be transformed upon MLL1 translocation. Our studies reveal a differential response of stem or progenitor populations to acute loss of MLL1 on proliferation and survival. These data suggest that the effects of MLL1 fusion oncoproteins will initiate the leukemogenic process differentially depending on the differentiation state of the cell type in which the translocation occurs.

Entities:  

Keywords:  HSC; MLL; leukemia; progenitors; proliferation; quiescence; trithorax

Mesh:

Substances:

Year:  2013        PMID: 23974107      PMCID: PMC3875671          DOI: 10.4161/cc.26032

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  11 in total

1.  The Pediatric Cancer Genome Project.

Authors:  James R Downing; Richard K Wilson; Jinghui Zhang; Elaine R Mardis; Ching-Hon Pui; Li Ding; Timothy J Ley; William E Evans
Journal:  Nat Genet       Date:  2012-05-29       Impact factor: 38.330

2.  Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Authors:  A V Krivtsov; M E Figueroa; A U Sinha; M C Stubbs; Z Feng; P J M Valk; R Delwel; K Döhner; L Bullinger; A L Kung; A M Melnick; S A Armstrong
Journal:  Leukemia       Date:  2012-12-13       Impact factor: 11.528

3.  Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.

Authors:  Shunya Arai; Akihide Yoshimi; Munetake Shimabe; Motoshi Ichikawa; Masahiro Nakagawa; Yoichi Imai; Susumu Goyama; Mineo Kurokawa
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

4.  An MLL-dependent network sustains hematopoiesis.

Authors:  Erika L Artinger; Bibhu P Mishra; Kristin M Zaffuto; Bin E Li; Elaine K Y Chung; Adrian W Moore; Yufei Chen; Chao Cheng; Patricia Ernst
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-06       Impact factor: 11.205

5.  Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic.

Authors:  Charles G Mullighan; Cheryl L Willman
Journal:  J Adolesc Young Adult Oncol       Date:  2011-06       Impact factor: 2.223

Review 6.  MLL translocations, histone modifications and leukaemia stem-cell development.

Authors:  Andrei V Krivtsov; Scott A Armstrong
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

7.  Different in vivo repopulating activities of purified hematopoietic stem cells before and after being stimulated to divide in vitro with the same kinetics.

Authors:  Naoyuki Uchida; Brad Dykstra; Kristin J Lyons; Frank Y K Leung; Connie J Eaves
Journal:  Exp Hematol       Date:  2003-12       Impact factor: 3.084

Review 8.  Childhood acute myeloid leukaemia.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba
Journal:  Br J Haematol       Date:  2012-09-12       Impact factor: 6.998

9.  Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors.

Authors:  Craig D Jude; Leslie Climer; Diyong Xu; Erika Artinger; Jill K Fisher; Patricia Ernst
Journal:  Cell Stem Cell       Date:  2007-09-13       Impact factor: 24.633

10.  MLL gene fusions in human leukaemias: in vivo modelling to recapitulate these primary tumourigenic events.

Authors:  S Rodriguez-Perales; F Cano; M N Lobato; T H Rabbitts
Journal:  Int J Hematol       Date:  2007-11-17       Impact factor: 2.490

View more
  7 in total

1.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Authors:  Sun-Mi Park; Mithat Gönen; Ly Vu; Gerard Minuesa; Patrick Tivnan; Trevor S Barlowe; James Taggart; Yuheng Lu; Raquel P Deering; Nir Hacohen; Maria E Figueroa; Elisabeth Paietta; Hugo F Fernandez; Martin S Tallman; Ari Melnick; Ross Levine; Christina Leslie; Christopher J Lengner; Michael G Kharas
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

2.  Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.

Authors:  Yufei Chen; Patricia Ernst
Journal:  Cell Cycle       Date:  2019-06-04       Impact factor: 4.534

Review 3.  A chromatin perspective on metabolic and genotoxic impacts on hematopoietic stem and progenitor cells.

Authors:  Zhenhua Yang; Hao Jiang
Journal:  Cell Mol Life Sci       Date:  2020-04-21       Impact factor: 9.261

4.  MLL1 Promotes IL-7 Responsiveness and Survival during B Cell Differentiation.

Authors:  Tao Gan; Bin E Li; Bibhu P Mishra; Kenneth L Jones; Patricia Ernst
Journal:  J Immunol       Date:  2018-01-19       Impact factor: 5.422

Review 5.  Molecular mechanisms of MLL-associated leukemia.

Authors:  Akihiko Yokoyama
Journal:  Int J Hematol       Date:  2015-03-17       Impact factor: 2.490

6.  MLL1 is essential for retinal neurogenesis and horizontal inner neuron integrity.

Authors:  Diana S Brightman; Rachel L Grant; Philip A Ruzycki; Ray Suzuki; Anne K Hennig; Shiming Chen
Journal:  Sci Rep       Date:  2018-08-09       Impact factor: 4.379

Review 7.  RNA Polymerase II-Dependent Transcription Initiated by Selectivity Factor 1: A Central Mechanism Used by MLL Fusion Proteins in Leukemic Transformation.

Authors:  Akihiko Yokoyama
Journal:  Front Genet       Date:  2019-01-14       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.